WallStSmart

Hinge Health, Inc. (HNGE)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 9524% more annual revenue ($56.58B vs $587.86M). NVS leads profitability with a 23.9% profit margin vs -89.9%. NVS earns a higher WallStSmart Score of 51/100 (C-).

HNGE

Hold

36

out of 100

Grade: F

Growth: 7.3Profit: 3.5Value: 6.0Quality: 5.0
Piotroski: 3/9Altman Z: -2.71

NVS

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 4.0Quality: 5.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HNGEUndervalued (+16.0%)

Margin of Safety

+16.0%

Fair Value

$46.15

Current Price

$45.45

$0.70 discount

UndervaluedFair: $46.15Overvalued
NVSSignificantly Overvalued (-52.5%)

Margin of Safety

-52.5%

Fair Value

$109.60

Current Price

$146.57

$36.97 premium

UndervaluedFair: $109.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HNGE2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
45.6%10/10

Revenue surging 45.6% year-over-year

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$282.11B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

HNGE4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Price/BookValuation
20.1x2/10

Trading at 20.1x book value

Return on EquityProfitability
-132.9%2/10

ROE of -132.9% — below average capital efficiency

EPS GrowthGrowth
-80.8%2/10

Earnings declined 80.8%

NVS4 concerns · Avg: 3.0/10
PEG RatioValuation
2.484/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-9.3%2/10

Earnings declined 9.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : HNGE

The strongest argument for HNGE centers on Revenue Growth, Debt/Equity. Revenue growth of 45.6% demonstrates continued momentum.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bear Case : HNGE

The primary concerns for HNGE are Piotroski F-Score, Price/Book, Return on Equity.

Bear Case : NVS

The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.

Key Dynamics to Monitor

HNGE profiles as a hypergrowth stock while NVS is a declining play — different risk/reward profiles.

HNGE is growing revenue faster at 45.6% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NVS scores higher overall (51/100 vs 36/100), backed by strong 23.9% margins. HNGE offers better value entry with a 16.0% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Hinge Health, Inc.

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Hinge Health, Inc. develops health care software for joint and muscle health. The company is headquartered in San Francisco, California.

Visit Website →

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?